Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer By Ogkologos - December 19, 2025 591 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an updated analysis of the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Five Questions With…Linda. April 7, 2022 Teenage (…and young adult) kicks April 5, 2023 How Can Occupational Therapy Assist with Chemotherapy-induced Peripheral Neuropathy? April 27, 2021 Combining existing drugs improves prostate cancer survival September 19, 2021 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Ivosidenib 6-Yr-Old With Cerebral Palsy Receives Dream Gift After Learning To Walk. Workout Wednesday – Upper Body Stretches Omission of Surgical Axillary Staging Noninferior To Sentinel Lymph Node Biopsy...
